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Abstract
Background: Myopia is a common visual disorder with increasing prevalence among developed countries of the
world. Myopia constitutes a substantial risk factor for several ocular conditions that can lead to blindness. The
purpose of this study is to conduct an overview of systematic reviews and meta-analyses in order to identify and
appraise robust research evidence regarding the management of myopia progression in children and adolescents.
Methods: A literature search will be conducted in MEDLINE, EMBASE, The Cochrane Database of Systematic
Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), and Health Technology Assessment (HTA)
Database via Centre for Reviews and Dissemination (CRD). We will search for systematic reviews or meta-analyses
that examine optical or pharmaceutical modalities for myopia control. Two independent overview authors will
screen the titles and abstracts against the eligibility criteria. Individual study’s methodological quality and quality of
evidence for each outcome of interest will be assessed by two independent authors using the ROBIS tool and
GRADE rating, respectively. In cases of disagreement, consensus will be reached with the help of a third author. Our
primary outcomes will be the mean change in refractive error, mean axial length change, and adverse events. A
citation matrix will be generated, and the corrected covered area (CCA) will be estimated, in order to identify
overlapping primary studies. Possible meta-biases and measures of heterogeneity will be described, and cases of
dual co-authorship will be identified and discussed. If any recently published randomized controlled trials (RCTs) are
detected, these will be appraised and their findings will be presented. An overall summary of outcomes will be
provided using descriptive statistics and will be supplemented by narrative synthesis.
Discussion: This overview will examine the high level of existing evidence for treatment of myopia progression.
Efficient interventions will be identified, and side effects will be reported. The expected benefit is that all robust
recent research evidence will be compiled in a single study. The results may inform future research in this area,
which should provide insight into the appropriate regimes for the administration of these modalities and
contribute to future guideline development.
Systematic review registration: PROSPERO CRD42017068204
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Background
Myopia is a common visual disorder with increasing preva-
lence among developed countries of the world. Current evi-
dence suggests that myopia affects a large portion of the
world population, reaching over 90% in Asian countries,
and typically develops in children of 6 to 8 years of age.
Over the past half-century, rapid progress of myopia has
been reported. Treatment of myopia at an early stage is of
paramount importance, as shortsightedness poses a signifi-
cant risk for several ocular disorders which could result in
blindness. These conditions include retinal detachment,
glaucoma, cataract, and macular degeneration [1].
A number of optical and pharmacological modalities have
been widely investigated for restriction of myopia progres-
sion [2, 3]. Clinical trials on spectacles, rigid gas permeable
contact lenses, progressive addition lenses, and soft contact
lenses have revealed little or no long-term efficacy of these
interventions in myopia control [4, 5]. Both tropicamide
combined with bifocals and timolol have also failed to show
a significant effect on slowing myopia progression [6, 7].
Two randomized controlled trials on pirenzepine revealed
encouraging findings; however, research has not been con-
tinued for this agent [8–10]. Contradictory evidence exists
regarding the effect of undercorrection on myopia progres-
sion. Two randomized controlled trials reported that
undercorrection enhances myopia development [11, 12].
Recent evidence shows that undercorrection restricts my-
opia progression compared to full correction in already my-
opic children, which is in line with former findings from
animal studies [13]. Acupuncture has also been investigated
for myopia control, but insufficient evidence exists regard-
ing its appropriateness for clinical use [14].
Recent studies have reported positive findings for atro-
pine eye drops and orthokeratology in the management of
juvenile myopia [15–18]. In addition, bifocal and multi-
focal soft contact lenses designed with new technology
constitute an emerging treatment with promising results
[19]. Increased outdoor exposure has also been described
to have a protective effect on myopia development [20].
Currently, there are no generally accepted guidelines
on the treatment of myopic progression. Various refract-
ive and pharmaceutical interventions have been investi-
gated, but atropine which appears the most beneficial
agent has not been approved by the Food and Drug Ad-
ministration (FDA). Associated adverse events have pre-
vented efficient interventions from becoming widely
adopted for myopia treatment [21, 22]. Myopia causes
considerable medical and economic impact on society.
The cost of treatment is significant to both individuals
and society. Annual expenses for myopia treatment are
estimated to be greater than for other ocular patholo-
gies, as well as for non-ocular chronic conditions. The
quality of life of individuals is also affected due to func-
tional, cosmetic, and psychological implications [23–25].
Further investigation is warranted, due to the existing
increasing prevalence of myopia in the worldwide popu-
lation [26]. Existing evidence, although at a high level,
has failed to convince ophthalmologists to uniformly
embrace treatments for myopia progression control. A
study design that has recently gained interest is the over-
view of systematic reviews or umbrella review that at-
tempts to bring together and treat synthetically the
evidence from systematic reviews with or without meta-
analyses in a given domain [27–29]. Thus, there is no
overview in existing literature synthesizing the informa-
tion provided by systematic reviews and meta-analyses
on slowing myopia progression in children, and this is
the aim of the present study.
Methods
Protocol and registration
This overview has been registered in the PROSPERO
database (CRD42017068204) and has been prepared in
consultation with the PRISMA-P statement [30, 31].
PRISMA-P checklist is provided as Additional file 1. Any
amendments to the protocol until completion of the over-
view shall be provided with reasons and shall be available
to public view.
Information sources and search strategy
A purposive literature search will be conducted in the
Cochrane Database of Systematic Reviews (CDSR), Data-
base of Abstracts of Reviews of Effects (DARE), and
Health Technology Assessment (HTA) Database via
Centre for Reviews and Dissemination (CRD) using the
keyword “myopia.” A more comprehensive search strat-
egy will be applied in MEDLINE and EMBASE, using
medical subject headings (MeSH) and text words related
to spectacles, contact lenses, anti-muscarinic agents, my-
opia, and children [4, 32]. Database search date is 15
January 2017. For all included studies, reference lists will
be also searched. MEDLINE search strategy and key-
words are provided in Additional file 2. No language,
study type, or date restrictions will be used.
Research question
What is the efficacy and safety of optical and pharmaco-
logical interventions used to control myopia progression
in children and adolescents?
Eligibility criteria
The overview question being addressed is best described
by the following PICOS (participants, intervention, com-
parator, outcomes, study design) format.
Participants
Our overview targets are children and adolescents, equal
to or less than 18 years of age (at baseline), diagnosed
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with myopia defined as spherical equivalent refraction ≤
− 0.25 diopters, with or without astigmatism, and with-
out any ocular comorbidities including strabismus and
amblyopia. Animals, adult population, patients not suf-
fering from myopia, or patients with myopia and strabis-
mus/amblyopia will be excluded. Studies related to
surgical interventions for myopia correction, e.g., refract-
ive surgery will not be considered.
Interventions
Any optical or pharmacological intervention for control-
ling myopia progression will be identified. No restriction
on duration and dose (if applicable) of treatment will be
imposed.
Comparators
Comparators will be the use of single-vision spectacles,
contact lenses, (sham) acupuncture, or placebo for con-
trolling myopia progression. No restriction on duration
of treatment will be imposed.
Outcomes
Our primary outcomes will regard myopia progression
and axial elongation as efficacy criteria. Myopia progres-
sion will be assessed as mean change in refractive error,
measured in diopters, per year. Mean change in axial
length, measured in millimeters, per year, will also be
evaluated. Outcomes reporting a change in other than a
12-month period will also be accepted and described.
Reported adverse events will be regarded as safety cri-
teria. A descriptive approach of side effects will be per-
formed, and odd ratios will be presented, if provided by
the authors.
Study design
We will consider systematic reviews or meta-analyses
of randomized controlled trials (RCTs), pseudo-RCTs,
and cohort and case-control studies. Network meta-
analyses, if available, will also be reviewed. In order
to ensure literature saturation, we aim to consider
any recently published RCTs found to not have been
included in the meta-analyses. Should recent RCTs be
identified, these will also be appraised and their find-
ings will be presented and discussed. No language
limitation will be imposed. Only human studies with
full text available will be analyzed.
Systematic reviews or meta-analyses of poor quality
cohort studies, case series, case reports, or expert
opinions will not be considered. Narrative reviews
that do not systematically search the literature and do
not critically appraise the quality of included studies
will be excluded.
Data management and extraction
Two independent authors will perform all screening steps.
Title and abstract screening will be conducted with the
Mendeley citation management software. The overview
authors will screen the titles and abstracts against the eli-
gibility criteria and obtain full reports for all titles that ap-
pear to meet the inclusion criteria, or where there is
uncertainty. One team of two independent overview au-
thors will manage data in duplicate from each eligible
study, using a data collection form in Microsoft Excel, de-
signed specifically to include all the data required. We will
only extract data of the included systematic reviews or
meta-analyses and not directly from the primary studies,
as this process would be beyond the scope of our over-
view. In cases of disagreement, consensus will be reached
with the help of a third author.
For each included study, information will be extracted
on the type of included study (systematic review, system-
atic review and meta-analysis, meta-analysis, or network
meta-analysis); publication date; number of databases
sourced and searched; last literature search; type of in-
cluded primary studies (randomized controlled trials, ob-
servational studies, or both); country/countries of origin
of studies included in each review; number of primary
studies in each review; source of financial support (if any);
participants’ characteristics (age range); total sample size
(or range of sizes of primary studies); type of treatment
(optical or pharmaceutical) and dose when applicable; type
of control (optical, pharmaceutical, or placebo) and dose
when applicable; follow-up period; outcomes that are rele-
vant to our overview question; results; major conclusions;
instrument used to appraise the primary studies and the
rating of their quality; metric used and effect size (for
meta-analyses); p-value (for meta-analyses); confidence in-
tervals (for meta-analyses); additional analyses (e.g. sub-
group analysis, meta-regression, sensitivity analysis, for
meta-analyses); and handling of heterogeneity (fixed/ran-
dom effects model, funnel plot, for meta-analyses).
Risk-of-bias assessment
Two overview authors will independently assess the
methodological quality of the included systematic re-
views and meta-analyses using the ROBIS tool. A quali-
tative, domain-based assessment will be performed with
ROBIS, evaluating eligibility criteria, identification and
selection of primary studies, data collection and study
appraisal, and synthesis and findings. A tabular presenta-
tion of ROBIS assessment for each included review will
be provided and will enable comparisons between stud-
ies and detection of the possible presence of bias [33].
We will also provide a table presenting a risk-of-bias as-
sessment of primary studies and relevant tool utilized by
each eligible review. If the risk of bias of primary studies
has not been evaluated by one or more reviews, we will
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appraise these studies and present our assessment in a
relevant table. The strength of evidence for each out-
come of interest across the eligible systematic reviews
will be evaluated by two independent authors using the
GRADE rating [34–36]. In order to minimize the sub-
jectivity of quality assessment process, a third reviewer
will be involved to resolve any discrepancies.
The list of included primary studies will be reviewed in
order to identify overlapping studies considered in two or
more eligible reviews. We will generate a citation matrix
presenting all the included reviews and primary publica-
tions. We will estimate the overlap by calculating the cor-
rected covered area (CCA), to assess if specific primary
studies are overrepresented. CCA will reflect the degree of
actual overlap, as it is not influenced by large reviews.
Should high or very high overlap be detected, we will re-
tain the review which will be (1) the most recent, (2) con-
taining a higher amount of information, and (3) the most
rigorous in terms of methodology, as assessed by ROBIS
tool and GRADE scale. We will examine and record
whether the results of overlapping studies are concordant,
and if many relevant primary studies would be excluded
as a result of the above approach [37].
Two independent overview authors will also examine
possible presence of meta-biases, including publication
bias, selective outcome reporting, and dual co-authorship.
Handling of heterogeneity for meta-analyses and other po-
tential sources of bias will be described [38–41].
Data synthesis
To summarize findings, a descriptive synthesis will be per-
formed. Specifically, we will provide tables that include
summaries of study characteristics, quality assessment,
and major conclusions. Methodological rigor and quality
of evidence of the included studies will be reflected by
ROBIS and GRADE assessments. The extent of overlap-
ping primary studies will be displayed in our citation
matrix, and the corrected covered area (CCA) will provide
an estimate of the actual overlap. Our overview outcomes
regarding the efficacy and safety of myopia treatments will
be stratified and presented according to the type of inter-
vention. For studies examining the same interventions, we
will state whether the reported conclusions are concord-
ant. Should any recent randomized controlled trials be
found to not have been included in the meta-analyses,
these will also be appraised and their findings will be pre-
sented and discussed.
Discussion
Currently, no consensus has been reached regarding the
management of myopic progression and no universal
guidelines have been established. This study aims to quali-
tatively synthesize systematic reviews and meta-analyses in
order to identify and appraise high-level research evidence
regarding myopia control in children and adolescents. Effi-
cient interventions will be identified and side effects will be
reported. Recently published randomized controlled trials
will also be presented to provide an insight into the most
recent available evidence for retarding myopia progression.
The results may guide future research in this area and con-
tribute to guideline development.
Additional files
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